SCHEMBL6760408

SCHEMBL6760408

COc1nccc(I)c1C(OC)OC

nearest known ligand 0.32

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNB2 O95067 2/20 0.32
CDK1 P06493 2/20 0.32
CCNB1 P14635 2/20 0.32
GSK3A P49840 2/20 0.32
GSK3B P49841 2/20 0.32
CDK5 Q00535 2/20 0.32
CDK5R1 Q15078 2/20 0.32
CCNB3 Q8WWL7 2/20 0.32
LRRK2 Q5S007 2/20 0.32
BTK Q06187 1/20 0.31
APLNR P35414 1/20 0.31
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31
CCR8 P51685 1/20 0.31
AURKA O14965 1/20 0.30
TTK P33981 1/20 0.30
AURKB Q96GD4 1/20 0.30
INCENP Q9NQS7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339030 0.78 MAPT (0.30)
SCHEMBL1019224 0.76 CCR1 (0.34) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL18180520 0.72 TRPA1 (0.35) LRRK2BTKAPLNRCCR1CCR5
SCHEMBL16914368 0.71 CCR4 (0.35) LRRK2APLNRCCR1CCR5CCR8
SCHEMBL17065367 0.71 AURKA (0.40) BTKAPLNRCCR1CCR5CCR8
SCHEMBL25343385 0.71 HPGD (0.40) LRRK2BTKAPLNRCCR1CCR5
SCHEMBL29879039 0.71 HPGD (0.40) LRRK2BTKAPLNRCCR1CCR5
SCHEMBL14853043 0.69 CCR1 (0.39) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL24457916 0.68 CCR1 (0.37) APLNRCCR1CCR5CCR8AURKA
SCHEMBL6762127 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6723853-B2 ANTICANCER AGENTS UNIVERSITY OF PITTSBURGH 2004-04-20 US disclosed
US-20030073840-A1 Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-04-17 US disclosed
WO-2003018559-A2 INTERMEDIATES AND PREPARATION THEREOF FOR THE ENANTIOSELECTIVE SYNTHESIS OF (20R) HOMOCAMPTOTHECINS UNIVERSITY OF PITTSBURGH (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073840-A1 Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins FOLR1, POR, FOLR2 CCNB2 935/4885CDK1 1105/4885CCNB1 825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.